An Update of the Efficacy and Comparative Characteristics of Direct (New) Oral Anticoagulants (DOACs) / Ozgur Karcioglu, Sarper Yilmaz, Göksu Afacan, Eylem Ersan, Derya Abuşka, Sehmus Zengin, Bilgen Ozkaya, Mandana Hosseinzadeh, Selman Yeniocak
Direct (New-generation) Oral Anticoagulants (DOACs) have emerged as effective agents which are used in place of vitamin-K antagonists in treatment and prophylaxis of Venous Thromboembolism (VTE), atrial fibrillation and other thrombotic diseases. Among them, the FIIa- direct thrombin inhibitor dabigatran and FXa inhibitors (rivaroxaban, apixaban, edoxaban) are the most broadly used. Anticoagulant dosing may differ under special considerations. The patients’ physiological reserves, organ functional status and failures should be taken into account in clinical decision-making processes. The advantages and drawbacks of each specific agent should be weighed with special regard to metabolism, pharmacokinetics and pharmacodynamics, along with the efficiency of the agents in different indications. This article aims to review the most recent literature to highlight the usage and efficacy of the agents in different clinical conditions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Cardiovascular & hematological agents in medicinal chemistry - 20(2022), 2, Seite 11 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Karcioglu, Ozgur [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (11 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL011163852 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011163852 | ||
| 003 | DE-627 | ||
| 005 | 20231128150430.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230613s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL011163852 | ||
| 035 | |a (KFL)prod_DARH_.4F4F791DCE3C7173C1BAC2B14ED24E172FB240CB | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Karcioglu, Ozgur |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a An Update of the Efficacy and Comparative Characteristics of Direct (New) Oral Anticoagulants (DOACs) |c Ozgur Karcioglu, Sarper Yilmaz, Göksu Afacan, Eylem Ersan, Derya Abuşka, Sehmus Zengin, Bilgen Ozkaya, Mandana Hosseinzadeh, Selman Yeniocak |
| 264 | 1 | |c 2022 | |
| 300 | |a 1 Online-Ressource (11 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Direct (New-generation) Oral Anticoagulants (DOACs) have emerged as effective agents which are used in place of vitamin-K antagonists in treatment and prophylaxis of Venous Thromboembolism (VTE), atrial fibrillation and other thrombotic diseases. Among them, the FIIa- direct thrombin inhibitor dabigatran and FXa inhibitors (rivaroxaban, apixaban, edoxaban) are the most broadly used. Anticoagulant dosing may differ under special considerations. The patients’ physiological reserves, organ functional status and failures should be taken into account in clinical decision-making processes. The advantages and drawbacks of each specific agent should be weighed with special regard to metabolism, pharmacokinetics and pharmacodynamics, along with the efficiency of the agents in different indications. This article aims to review the most recent literature to highlight the usage and efficacy of the agents in different clinical conditions | ||
| 700 | 1 | |a Yilmaz, Sarper |e verfasserin |4 aut | |
| 700 | 1 | |a Afacan, Göksu |e verfasserin |4 aut | |
| 700 | 1 | |a Ersan, Eylem |e verfasserin |4 aut | |
| 700 | 1 | |a Abuşka, Derya |e verfasserin |4 aut | |
| 700 | 1 | |a Zengin, Sehmus |e verfasserin |4 aut | |
| 700 | 1 | |a Ozkaya, Bilgen |e verfasserin |4 aut | |
| 700 | 1 | |a Hosseinzadeh, Mandana |e verfasserin |4 aut | |
| 700 | 1 | |a Yeniocak, Selman |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiovascular & hematological agents in medicinal chemistry |d Sharjah, U.A.E. : Bentham Science Publishers, 2006 |g 20(2022), 2, Seite 11 |h Online-Ressource |w (DE-627)KFL00000653X |w (DE-600)2254230-9 |w (DE-576)273891049 |x 1875-6182 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2022 |g number:2 |g pages:11 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1871-5257&volume=20&issue=2&spage=114 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_DARH_03 | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2022 |e 2 |h 11 | ||